Leukemia, Myeloid: all 2,432 studies
Page 21 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL PositiveCompletedNCT00763763Phase 2
- Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid LeukemiaCompletedNCT00762632Phase 1/2
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
- Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy SubjectsCompletedNCT00759837Phase 1
- Nilotinib Pre and Post Allogeneic Stem Cell TransplantationCompletedNCT00750659Phase 2
- Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive ChemotherapyCompletedNCT00739388Phase 2
- Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid LeukemiaWithdrawnNCT00732186Phase 1
- Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction TherapyStatus unknownNCT00728520Phase 2
- Oral Clofarabine for Acute Myeloid LeukemiaCompletedNCT00727766Phase 1
- The Effectiveness of the Neutropenic Diet in Pediatric Oncology PatientsCompletedNCT00726934Not applicable
- Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)TerminatedNCT00720850Phase 2
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2
- Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2Status unknownNCT00718250Phase 1
- Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE StudyStatus unknownNCT00715637Phase 3
- Decitabine and Bortezomib in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00703300Phase 1
- BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid LeukaemiaCompletedNCT00701766Phase 2
- Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic MalignanciesCompletedNCT00697671Phase 1
- Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)CompletedNCT00689000Phase 1/2
- Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantTerminatedNCT00674427Phase 1
- A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following TransplantationTerminatedNCT00672152Phase 1
- Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT00671697Phase 1
- Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT00666497Phase 2
- Phase 1 Study of Terameprocol (EM-1421) in Patients With LeukemiaTerminatedNCT00664677Phase 1
- Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to GleevecCompletedNCT00661180Phase 2
- Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological MalignanciesCompletedNCT00660920Phase 1
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid LeukemiaTerminatedNCT00660036Phase 1
- Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional CytarabineTerminatedNCT00655395Phase 1/2
- Velcaflagida in Relapsed or Refractary Acute Myeloid LeukemiaCompletedNCT00651781Phase 1/2
- Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid TumorsCompletedNCT00640796Phase 1
- A Study of ARRY-520 in Patients With Advanced Myeloid LeukemiaCompletedNCT00637052Phase 1/2
- Everolimus (RAD001) in Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT00636922Phase 1
- Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to TreatmentCompletedNCT00632255
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00624936Phase 1
- Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric MalignanciesCompletedNCT00619879
- A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid LeukemiaWithdrawnNCT00601991Phase 2
- A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid LeukemiaWithdrawnNCT00594555Phase 2
- Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years OldCompletedNCT00590837Phase 3
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
- Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal TumorsCompletedNCT00580281Not applicable
- Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT00577694Phase 1
- Investigation of the Cylex® ImmuKnow® AssayCompletedNCT00569842
- A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid MalignanciesTerminatedNCT00569179Phase 1
- FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AMLStatus unknownNCT00559221Phase 2
- A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic LeukemiaCompletedNCT00559091Phase 2
- A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in ChinaCompletedNCT00559065
- Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid LeukemiaStatus unknownNCT00544999Phase 1
- Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid LeukemiaTerminatedNCT00543972Phase 1
- Natural Killer Cells in Older Patients With Acute Myeloid LeukemiaCompletedNCT00540956Not applicable
- Prospective Database for Chronic Myelogenous LeukemiaStatus unknownNCT00538447Not applicable
- An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00538109Not applicable
- Reduced Intensity AlloSCT in(CML) With Persistent DiseaseTerminatedNCT00531310Phase 2
- Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)CompletedNCT00530699Phase 1
- Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALLCompletedNCT00529360Phase 1/2
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous LeukemiaCompletedNCT00528983Phase 1
- Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)Active, not recruitingNCT00525746
- Study to Assess the Safety of Escalating Doses of AT9283, in Patients With LeukemiasTerminatedNCT00522990Phase 1/2
- A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two GroupsCompletedNCT00521664Phase 3
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCTCompletedNCT00516152Phase 2
- Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic PhaseCompletedNCT00514969Phase 2
- Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic MalignanciesTerminatedNCT00514722Not applicable
- Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)CompletedNCT00514488Phase 3
- Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell VaccinesTerminatedNCT00514189Phase 1
- Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic MalignanciesTerminatedNCT00513318
- Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic AnemiaCompletedNCT00513175
- Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid LeukemiaCompletedNCT00512083Phase 2
- Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid LeukemiaCompletedNCT00511303Phase 2
- Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)TerminatedNCT00511121Phase 2
- Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid LeukemiaStatus unknownNCT00510939Phase 2
- Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT00510926Phase 2
- VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous LeukemiaCompletedNCT00505700Phase 1
- Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome PatientsCompletedNCT00504920
- Molecular Epidemiology of Acute Myelogenous LeukemiaStatus unknownNCT00502983
- A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)TerminatedNCT00500006Phase 1
- Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00497991Phase 1
- Treosulfan-based Conditioning for Transplantation in AML/MDSCompletedNCT00491634Phase 2
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00488709Phase 4
- SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
- Nilotinib as First-line Treatment of Ph+ CML in Early Chronic PhaseCompletedNCT00481052Phase 2
- Lomustine and Intermediate Dose Cytarabine in Older Patients With AMLCompletedNCT00480064Phase 3
- Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid LeukemiaCompletedNCT00478985Not applicable
- NOPHO-AML 2004 Study for Children With Acute Myeloid LeukemiaCompletedNCT00476541Phase 3
- High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AMLCompletedNCT00474006Phase 3
- Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT00470197Phase 1
- Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative TherapyCompletedNCT00469729Phase 2/3
- Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 YearsCompletedNCT00464217Phase 4
- Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic LeukemiaTerminatedNCT00464113Phase 1
- Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on ImatinibTerminatedNCT00461929Phase 4
- Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological MalignanciesCompletedNCT00460694Phase 1/2
- Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic TransplantationCompletedNCT00460629Phase 1/2
- Gemtuzumab Ozogamicin Before Allogeneic Stem Cell TransplantationStatus unknownNCT00460447Phase 1/2
- Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT00459524
- GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00459212Phase 1
- Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1HCompletedNCT00458250Phase 1
- Safety Assessment of a Multipeptide-gene Vaccine in CMLCompletedNCT00455221Phase 1
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2/3
- Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesCompletedNCT00451997Phase 2
- Intermittent Liposomal Amphotericin B Primary ProphylaxisStatus unknownNCT00451711Phase 2
- AML Treatment in Untreated Adult PatientsStatus unknownNCT00449319Not applicable
- A Phase II Study of Maintenance With Azacitidine in MDS PatientsTerminatedNCT00446303Phase 2